AllianceBernstein
DRUG

AllianceBernstein’s Bright Minds Biosciences DRUG Stock Holding History

AllianceBernstein’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$414K Buy
+5,680
New +$446K ﹤0.01% 2829

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

AllianceBernstein's DRUG Position: Q2 2026 in Review

AllianceBernstein opened a new position in Bright Minds Biosciences (DRUG) in Q2 2026: 5,680 shares worth $414K. The stake represents ﹤0.01% of the portfolio and ranks #2829 among its holdings.

100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • AllianceBernstein held 5,680 shares of Bright Minds Biosciences worth $414K as of Q2 2026.
  • Bright Minds Biosciences was a new AllianceBernstein position in Q2 2026.
  • Bright Minds Biosciences made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2829 holding.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.